EIF4G2 Antibody | 18-858

EIF4G2 Antibody | 18-858 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: A synthetic peptide corresponding to a sequence within amino acids 750-850 of human EIF4G2 (NP_001409.3) .

Research Area: Apoptosis, Cell Cycle

Tested Application: WB, IHC

Application: WB: 1:500 - 1:1000
IHC: 1:100 - 1:200

Specificiy: N/A

Positive Control 1: SW480

Positive Control 2: A-549

Positive Control 3: BT-474

Positive Control 4: 293T

Positive Control 5: SH-SY5Y

Positive Control 6: Mouse kidney

Molecular Weight: Observed: 102kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: EIF4G2, AAG1, DAP5, FLJ41344, NAT1, p97, P97

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Translation initiation is mediated by specific recognition of the cap structure by eukaryotic translation initiation factor 4F (eIF4F) , which is a cap binding protein complex that consists of three subunits: eIF4A, eIF4E and eIF4G. The protein encoded by this gene shares similarity with the C-terminal region of eIF4G that contains the binding sites for eIF4A and eIF3; eIF4G, in addition, contains a binding site for eIF4E at the N-terminus. Unlike eIF4G, which supports cap-dependent and independent translation, this gene product functions as a general repressor of translation by forming translationally inactive complexes. In vitro and in vivo studies indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. Alternatively spliced transcript variants encoding different isoforms of this gene have been described.